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Abstract
Background: HPV is the major etiological factor in the causal pathway for cervical cancer, which is the leading
cancer among women in sub-Saharan Africa. HIV is associated with a higher prevalence and a broader range of
high-risk HPV genotypes. Studies have shown a positive association between Bacterial vaginosis (BV) and HPV
and HIV. Also, in African women, BV was found to be significantly associated with vaginal inflammation. The high
prevalence of BV, HIV and HPV infections in the African continent makes elucidation of the interactions with one
another of utmost public health interest. The aims of the current study are to examine the frequency of HPV
genotypes and BV as well as their respective risk factors within an HIV infected population with abnormal cytology
in the resource-constrained setting of Mombasa, Kenya and, secondly, highlight issues to consider for triple
co-infection clinical management.
Method: Cross-sectional analysis with a sample drawn from an ongoing cohort study. All consenting, non-pregnant
HIV infected women, between 18 and 50 years of age, without a history of cervical cancer or hysterectomy, between
November 2005 and April 2006 were screened for HR HPV DNA in Mombasa, Kenya. 1 out of 4 HIV positive women
fulfilled the criteria by having SIL (24.9 %). 600 HIV infected women were tested to reach a cohort of 74 HIV women
with abnormal cytology. To assess which factors were associated with HR HPV, crude statistical analysis was performed
through logistic regression.
Results: Bacterial vaginosis (BV) was found in 46 women out of 74 (62.2 %). Cervicitis was diagnosed in 15 %
of women (n = 11), of which 8 had BV. The most prevalent HPV genotypes were HPV 16 (33.8), HPV 53 (24.3)
and HPV 18 (17.6 %), while 65 % of the participants had multiple genotype infection.
Statistically significant associations between CD4 counts <200 cells/μl and multiple HPV prevalence, adjusted
for age were also noted (OR = 3.7; 95 CI: 1.2–12.1; p = 0.03) and HPV53 (OR = 4.4, 95 % CI: 1.4–13.6; p = 0.01).
A statistically significant association was found between CD4 count ≥ 350 μl and HPV 16 adjusted for age
(OR = 2.9; 95 % CI: 1.0- 8.3; p = 0.05). A borderline statistically significant association was observed between
BV and HPV58 (crude OR = 4.1, 95 % CI: 0.8–21.0; p = 0.07).
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Conclusion: The most prevalent HPV genotypes observed were HPV 16, HPV 53, and HPV 18, which have a
combined prevalence of 76 %. Our results show that a triage based on CD4 count should start at CD4 count≥ 350 μl
as our study suggests that HPV 16 are more prevalent when women are moderately immunosuppressed. Given the
high prevalence of HPV 53 in a HIV infected population with abnormal cytology, its cervical carcinoma genesis
potential as a stand-alone genotype and as well as its synergism with multiple infections should be investigated.
The new WHO guideline in resource-poor settings to rescreen women for HPV within ten years may be more
effective if BV and cervicitis management become a major component for HIV-HPV management.
Keywords: HIV, HPV, CD4 count, BV, Cervicitis
Background
Cervical carcinoma is the fourth most prevalent cancer
in the world and the most common female cancer in
sub-Saharan Africa [1]. It is the second most prevalent
cancer among women in Kenya, after breast cancer, and
its incidence is increasing [2].
Infection with a high risk (HR) Human Papillomavirus
(HPV), a sexually transmitted DNA virus, is the central
etiological agent in the development of cervical cancer
and include HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68 [3]. Others HPV types 26, 53, 66,
67, 70, 73, and 82 are classified as “possible/probable”
(pHR) carcinogens according to the recent review of
International Agency for Research on Cancer (IARC)
assessing carcinogenicity of biological agents [4]. The 15
HR oncological viral strains, which have been identified
can be broken down into the HPV 16 group (alpha-9) of
the alpha-papillomavirus genus (HPV 31, HPV33, HPV
35, HPV 52, and HPV 58) and the HPV 18 group
(alpha-7; HPV39, HPV 45, HPV 59, and HPV 68) [5, 6].
Cervical cancer is the result of a change in the cell
cycle control caused by HP. Cervical intraepithelial neo-
plasia (CIN) can be histologically graded into mild dyspla-
sia (CIN 1), moderate dysplasia (CIN 2), and both severe
dysplasia and carcinoma in situ belonging to CIN 3 [7].
Apart from a higher prevalence and broader range of
HR HPV, HIV immunosuppression has been linked to
multiple HPV infection [8, 9], particularly in those with
CD4 count <200 cells/μl [10], meaning when immuno-
suppression becomes severe. Multiple HPV genotypes
co-infections has been attributed to the inability to clear
HPV infections as well as to the reactivation of latent
HPV infections, both occurring as a result of immune
suppression [6, 8, 11, 12]. In a recent large study on
multiple HPV infections in Costa Rica, young non-HIV
positive women with multiple infections were observed
to be at significantly increased risk of CIN 2+, when
compared with those with single infections [13, 14].
Moreover, concurrent genital infections are common
in HIV-1–infected women. The prevalence of Bacterial
Vaginosis (BV), characterized by an overgrowth of vagi-
nal anaerobic flora and reduction of H202-producing
lactobacilli in African women is among the highest world-
wide [15], which is of particular concern, as there is
evidence that BV is a risk factor for acquisition and trans-
mission of many STI’s, including HIV and HPV [16, 17]. A
recent meta-analysis of available literature also suggested
a positive association between BV and HPV infection,
though no study in Africa was eligible to be included [18].
A recent HIV Epidemiology Research study in Tanzania
showed that BV is also associated with increased odds for
incident HPV as well as delayed clearance among women
[19]. These findings are in line with biologic plausibility
since, unlike most cervical HPV infections, BV causes
major changes in the local vaginal environment leading to
degradation of innate defenses.
In previous studies, BV was associated with many sexu-
ally transmitted infections (STIs), including infection with
Chlamydia trachomatis, Neisseria gonorrhoea, HSV-1 and
2 [20–22]. Also, there is evidence that BV is an independ-
ent predictor for HPV 16 and its related genotypes [23].
There is growing evidence from other studies that BV is
an independent risk factor for cervicitis [24]. BV could
lead to cervicitis through a loss of bactericidal H202-
producing lactobacilli, reduced levels of protective vagi-
nal mucins, and increased pro-inflammatory enzymes
and cytokines, which in turn may decrease the cervical
mucus barrier [24].
New guidelines from WHO in December 2014 advo-
cates for a “screen and treat” approach in resource poor
settings, in which treatment of detected precancerous
lesions ensues Visual Inspection with Acetic acid (VIAC)
or HPV testing for screening soon or immediately [25].
The use of HPV tests for cervical cancer prevention is
expected to reduce the frequency of screening and “once
a woman has been screened negative, she should not be
rescreened for at least 5 years, but should be rescreened
within ten” [23]. However, there is current scant evi-
dence to support the adequateness of this guideline in
HIV-infected women living in low resource settings.
Screening programs need to be tailored to the resources
and capacity in each area. This secondary preventive
strategy would accompany the comprehensive strategy
to prevent cervical cancer in Kenya, which includes
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plans for vaccinating girls with the quadrivalent vaccine
(Gardasil™) by 2015 [26, 27].
This analysis of HIV-positive women with abnormal
cytology purports to test our a priori hypotheses that
HPV 53, being more prevalent in HIV-infected women
is associated with immunosuppression and that BV is
associated with genotypes pertaining to the alpha-group.
The objectives are threefold: 1) to describe the distribu-
tion of HPV genotypes and multiple HPV infections,
cervicitis, BV and STIs within our population; 2) to
explore whether low CD4 count is a predictor for
multiple HR HPV genotypes and the most prevalent
pHR/HR HPV genotypes and BV a predictor for alpha 9
related genotypes as well as the most prevalent pHR/HR
HPV genotypes 3) discuss the potential effectiveness of a
screening protocol triaged by CD4 count and age and
the public heath management of HIV-HPV-BV.
Methods
This cross-sectional analysis reports the findings of a
sample of women enrolled in a prospective cohort study,
whose aim was to define the best way to manage low
grade squamous intraepithelial lesions in HIV-1 infected
women, aged between 18 and 50 years in Mombasa,
Kenya, between November 2005 and April 2006. As all
women were to receive the same intervention depending
on their squamous intraepithelial lesion, no formal sample
size calculation was needed. 600 women were screened
within this period. Non-pregnant women of reproductive
age and attending the Comprehensive Care Centre for
management of HIV infection at Coast Province General
Hospital in Mombasa, Kenya, were invited to participate.
Within the 600 HIV positive women undergoing cyto-
logical examination, we expected to find 10 % prevalence
of Squamous Intraepithelial Lesions (SIL) for the HIV
positive patients not on HAART and 15 % for those under
HAART period, resulting in 74 HIV women with abnor-
mal cytology being recruited from the initial cohort.
Cytological abnormalities, a prerequisite for partici-
pating in the study, were all histologically confirmed.
Exclusion criteria included pregnancy, less than 6 weeks
post-partum, history of cervical cancer or hysterectomy.
Self-reported behavioral risk factor assessment included
the presence of an STI, number of sexual partners, the
age of first sexual intercourse and regular use of a
condom. Blood plasma samples for measuring CD4
count were taken, and a gynaecological examination
was performed with speculum insertion, and collection
of endocervical and high vaginal swabs.
Biologic specimens
Cervical samples were collected using a cervix brush
(Cervex-brush®, Rovers®, Oss, The Netherlands), and cer-
vical cytology was assessed with conventional Papanicolaou
(Pap) smears. Slides were read by a cytologist with
master level training, supervised by a pathologist. An
external cytopathologist provided quality control. The
Bethesda Reporting System was used for cytological
classification [28].
The cervix brush tips were preserved in a liquid-based
cytology collection medium (SurePath®, Tripath Imaging
Inc., Burlington, North Carolina, USA) and stored at
4 °C until further processing.
HPV DNA extraction, detection and typing
HPV testing was done as described by Depuydt et al.
(2006) Micalessi IM et al. (2012) in an accredited labora-
tory (ISO certification: ISO15189) [29, 30]. Briefly, HPV
DNA was extracted from exfoliated cervical cells using
the standard proteinase K-based digestion protocol, fol-
lowing the manufacturer’s instructions. Cells were incu-
bated with proteinase K solution (100 μg/ml) for 3 h at
55 °C. DNA was then further purified by spin column
chromatography. HPV types were determined using a
series of real-time PCR reactions with specific primers
and TaqMan® (Invitrogen, La Jolla, USA) probes for HR
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66 and 68 IARC (2006). Low risk (LR) HPV types 6
and 67 were also detected. HPV DNA was tested accord-
ing to de Meijers’ et al. (2009) guidelines for HPV DNA
test requirements [31].
The national recommendation was followed to diagnose
HIV and a parallel testing algorithm was used for HIV diag-
nosis using rapid immunoassays: Uni-Gold™ Recombigen®
HIV (Trinity Biotech plc, Bray, Ireland) and Determine®
HIV-1/2 (Abbott Japan co Ltd, Minato-Ku, Tokyo, Japan).
In the case of indeterminate results, an enzyme-linked
immunosorbent assay was used to confirm HIV status.
Diagnosis of STIs
A gynecological examination was performed and blood,
urine, PAP smear, and high vaginal and endocervical
swabs collected. PAP smears were read using conventional
cytology and classified using the Bethesda classification.
Infection with Trichomonas vaginalis was determined by
wet mount and/or PAP smear slides. To test for Neisseria
gonorrhoeae infection, culture plates (blood agar; Inter-
national Diagnostic Group, Lancashire United Kingdom)
were inoculated with endocervical swabs Presence of HIV
was confirmed in the patient’s serum using a parallel
algorithm comprising Uni-Gold® HIV (Trinity Biotech plc,
Bray, Ireland) and Determine® HIV-1/2 (Abbott Japan co
Ltd, Minato-Ku, Tokyo, Japan). Elisa was used when paral-
lel test results were discordant.
Cervicitis
Cervicitis was diagnosed from inflammatory cells by means
of a microscopic test.
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Statistical analysis
Analysis was done using STATA version 12 (Stata-Corp
LP, College Station, TX).
Age was dichotomized into > 30 years and ≤ 30 years;
this categorization was used to reflect the WHO 2014
guideline concerning cervical screening. Condom use
was dichotomized as always or irregular, according to
self-report. CD4 cell count was analyzed both as a con-
tinuous variable and as two categorical variable, using a
cut off of CD4 count <200 cells/μl (vs ≥ 200 cells/μl) and
CD4 count <350 cells/μl (vs ≥350 cells/μl), when HIV in-
fected women are severely immunosuppressed and mod-
erately immunosuppressed, respectively. The number of
sexual partners was also dichotomized as per other studies
(up to 5 versus 6 or more), this dichotomization was used
to make our studies more comparable to others and to
explore the risk from a public health point of view.
The method employed for the first objective was to
calculate the proportion of the specific HPV genotype di-
vided by 74 (the sample size), the number of co-infected
women with abnormal cytology, as well as the proportion
of STI, BV and cervicitis, along with a 95 % CI. For the
second objective, logistic regression analysis was per-
formed to identify risk factors for HR-HPV. This included
the associations between low CD4 count and the most
prevalent pHR/HR HPV genotypes (as well as the one
between BV and alpha 9 phylogenetically-related geno-
types and most prevalent pHR/HR HPV genotypes. This
outcome variable was dichotomized into low-risk HPV
(LR-HPV) and absence of HPV genotypes versus HR-HPV
genotypes (see above). The resulting odds ratio was used
to measure the strength of the association between HPV
infection and each risk factor in turn. A multivariable
logistic regression analysis was performed to simultan-
eously control for potential confounders and to assess the
adjusted association for various risk factors. To assess the
impact of CD4 count on the effects of the parameters,
interaction parameters were assessed in the models by
doing a Wald test. As no interaction terms were signifi-
cant, no model reflecting the differential impact for that
particular outcome was included.
The same method was also used to explore the simultan-
eous effect of age and number of sexual partners on the
HPV genotype and to explore whether there was an associ-
ation between the two or more HR HPV co-infections and
CD4 count, while adjusting for age and the number of
sexual partners.
Statistical tests were considered significant when the
p-value, derived from the Wald Test, is 0.05 or less.
Ethical considerations
Staff obtained written informed consent from patients,
collected demographic and behavioural data using struc-
tured questionnaires. All human subject protocols were
approved by the Ethics Committee at the Kenyatta
National Hospital, which also gave overall ethical ap-
proval for this study (Ref: KNH-ERC/01/3618).
Results
Characteristics of the population
The study included 74 non-pregnant HIV-infected women
with an abnormal cytology. The mean age was 34.2 years
of age (SD = 6.5). The median age at first sexual inter-
course was 18.0 (IQR: 15.5–20.0). The median number of
sex partners was 2 (IQR: 1–4). The median CD4 count
was 236 cells μl/(IQR: 158–374). The mean number of
HR HPV genotypes per participant was 2.3 (SD = 1.6). The
majority of patients (82 %) were under treatment with
highly active antiretroviral therapy (HAART) (Table 1).
Concerning sexual behavior, 81.8 of women reported
irregular use of condoms, and 87.9 % had up to 5 sexual
partners (Table 1).
Prevalence of cervical abnormalities
Atypical squamous cells with possible high significance
(ASC-H) were detected in 4.0 %, atypical squamous cells
of undetermined significance (ASC-US) in 16.2, LSIL
58.1 and HSIL in 20.3 % of the patients.
Histology results found the following abnormalities:
Cervical intraepithelial neoplasia (CIN I) in 58.3 %, CIN
2+ 43.2 %, of which 1 had ICC. Cervicitis was recorded
in 15 and normal biopsy in 4.0 % of the participants. In
5 women with CIN 1, HPV was absent and in the two
normal biopsies, HPV was present.
Table 1 Distribution of various categorical variables: age, sexual
behaviour and CD4 count
Variable N Percentage (95 % CI)
Age group:
> 30 years 54 73.0 % (61.4–82.6)
≤ 30 years 20 27.0 % (17.4–38.6)
Sexual behaviour:
First sexual encounter <15 years old 29 60.4 % (52.7–74.2)
First sexual encounter > =15 years old 19 39.6 % (25.8–54.7)
> 6 sexual partners 7 12.1 % (5.0–23.3)
≤ 5 sexual partners 51 87.9 % (76.7–95.0)
Regular use of condom 10 18.2 % (9.1–30.9)
No regular use of condom 45 81.8 % (71.3–92.3)
CD4 count:
CD4 count <200 cells/μl 26 35.1 % (24.0–46.3)
CD4 count ≥200 cells/μl 48 64.9 % (69.1–91.0)
CD4 count <350 cells/μl 52 70.3 % (58.5–80.3)
CD4 count ≥350 cells/μl 22 29.7 % (19.1–40.4)
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Prevalence of HPV genotypes
The most prevalent HPV genotypes found in this HIV-
infected cohort of women are displayed in Table 1. HPV
16 and 53 were the most prevalent, with 34.8 and 24.3 %,
respectively followed by HPV 18 with 17.6 % (Table 2).
A large proportion, 64.9 %, of the women in this cohort
has multiple HPV genotypes (Table 2). Most multiple
infections were dual infections, (24 %), but two women
had up to 7 co-infections (Table 3).
At least one of the HR HPV genotypes was observed
in 86.5 of the women, 5.4 with LR-HPV types and 8.1 %
without any contemporaneous HPV infection.
Prevalence of concurrent STIs
STIs were observed in 68.9 of all women, and 15.7 %
had more than 1 STI co-infection (Table 1). 16.2 were
diagnosed with genital ulcer disease, 1.4 trichomonas
vaginalis and 10.8 % had genital warts.
Sexually enhanced disease
Out of the 11 women with cervicitis, 8 had BV.
Risk factors for specific HR-HPV infection: results of
uni- and multivariable analysis
No significant association was observed between HPV
16 and age (OR = 1.4; 95 % CI: 0.5–3.6; p = 0.5), adjusted
for ≥6 sexual partners (aOR = 1.1; 95 % CI: 0.3–4.1; p =
0.8); HPV 53: (OR = 05; 95 % CI: 0.2–1.6; p = 0.3) adjusted
for ≥6 partners (aOR = 0.9; 95 % CI: 0.2–3.2; p = 0.8) and
HPV 18 (OR = 0.4; 95 % CI 0.1–1.6; p = 0.2): adjusted for
≥6 partners (OR = 2.3; 95 % CI: 0.5–11.5; p = 0.3). No sig-
nificant association was found for multiple HPV genotypes
and age (OR = 1.8; 95 % CI: 0.6–5.1; p = 0.3) and adjusted
for sexual partners (OR = 2.4; 95 % CI: 0.7–8.9; p = 0.2)
(Table 4).
CD4 count
35.1 % women had low CD4 counts <200 cells/μl and
64.9 % had high CD4 count ≥200 cells/μl. 70.3 had CD4
count <350 cells/μl and 29.7 % had CD4 count ≥350
cells/μl (Table 3). The OR obtained from the logistic
regression yielded a statistically significant association
between CD4 < 200 μl and multiple HPV co-infections
(OR: 3.7; 95 % CI: 1.2–12.1; p = 0.03) but a non-significant
association between CD4 count ≥350 cells/μl and multiple
HPV infections (OR: 0.7; 95 % CI: 0.3–2.0; p = 0.5). Low
CD4 counts <200 cells/μl was found to be a significant
predictor of only HPV 53 (age-adjusted OR = 4.4, 95 % CI:
1.4–13.6; p = 0.01) and HPV 16 (age-adjusted OR = 2.9;
95 % CI: 1.0–8.3; p = 0.05) (Table 4).
A t-test indicated that women with CD4 count <200
cells/μl have a significantly higher mean of prevalent HPV
infections (mean of pHR HPV genotypes coinfections =
3.03) compared to women with CD4 count >200 (mean of
pHR HPV genotypes coinfections = 2.0) : (p = 0.006 for the
difference in mean). However, there was no significant
difference (p = 0.5) between women with a CD4 count
Table 2 Prevalence of pHR/HR and low risk HPV infection and
other sexually transmitted infections
Type of infection N Percentage (95 % CI)
HR HPV:
HPV 16 25 33.8 % (22.8–44.8)
HPV 18 13 17.6 % (8.7–26.4)
HPV 31 11 14.9 % (6.6–23.2)
HPV 33 12 16.2 % (7.6–24.8)
HPV 35 13 17.6 % (8.7–26.4)
HPV 45 3 4.1 % (0.5–8.7)
HPV 39 8 10.8 % (3.6–18.1)
HPV 51 11 14.9 % (6.6–23.2)
HPV 52 15 20.3 % (10.9–29.6)
HPV 53 18 24.3 % (14.3–34.4)
HPV 56 15 20.3 % (10.9–29.6)
HPV 58 13 17.6 % (8.7–26.4)
HPV 66 11 14.9 % (6.6–23.2)
HPV 68 4 5.4 % (0.1–10.7)
Multiple HR HPV 48 64.9 % (53.7–76.0)
Women on HAART 60 82.0 (80.0–90.2)
LR HPV:
HPV 6 4 5.4 % (4.4–6.4)
HPV 67 0 0
No HPV infection: 6 8.1 % (3.0–16.8)
STIs:
BV 46 62.2 % (50.9–73.5)
Genital ulcer 12 16.2 % (7.6–24.8)
Genital warts 8 10.8 % (3.6–18.1)
Trichomonas vaginalis 1 1.4 % (0.1–4.0)
Cervicitis 11 14.9 % (6.6–23.2)
STI prevalence 51 68.9 % (58.1–79.7)
More than one STI 8 10.7 % (3.5–17.8)
Table 3 Prevalence of multiple HPV genotypes among the total
sample size (N = 74)
Number of co-infections n. %
2 co-infections 18 24 %
3 co-infections 12 16 %
4 co-infections 12 16 %
5 co-infections 3 4 %
6 co-infections 1 1 %
7 co-infections 2 3 %
Total 48 65 %
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<350 cells/μl (mean = 2.4) in and women with CD4 count
≥350 cells/μl (mean = 2.1).
Micro-organisms
68.9 had a concomitant STI, and 62.2 % women had BV
(Table 1). With the exception of HPV 58 (OR = 4.1; 95 %
CI: 0.8–21.0, p = 0.07), no significant association was
found between BV and HPV 16 and its phylogenetically-
related genotypes, HPV 31, HPV 33, HPV 58, HPV 52
(Table 5).
Discussion
Summary of results and comparison with other studies
Our analysis shows that the most common pHR/HR
HPV genotypes, HPV 16, followed by HPV 53 and HPV
18, with a combined prevalence of 76 %, were found
in presence of other pHR/HR HPV infections. Strong
associations were observed between HPV 53 and multiple
HR HPV infections with CD4 count <200 cells/μl.
In agreement with studies showing HPV 16 to be the
least affected by diminished immunity [12], we found
that women with CD4 < 200 cells/μl had a 26.9 % preva-
lence of HPV 16 compared to 37.5 % in women with CD4
count >200/μl and a statically significant association be-
tween women with CD4 count ≥350/μl when adjusted for
age. One study in Kenya found a significantly higher
prevalence of HPV 16 in an HIV clinic where the median
CD4 count at recruitment was 407 cells/μl [32]. Other
studies in Kenya lacked stratification of HPV 16 and HPV
18 by HIV status and CD4 count. In a family planning un-
selected study conducted in Nairobi, it was observed that
less than 10 % had HPV 16 and/or 18 these types were
present in about 40 % of HSIL lesions [33]. In a study on
FSW in Kenya, HIV infected women with normal cytology
had an HPV 16 or 18 prevalence of 9.6 % [33], though the
prevalence of either HPV is unknown in HIV infected
women with abnormal cytology [34]. A hypothesis is that
HPV16 may be more sensitive to attack from other geno-
types, and thus may be at higher risk of competition when
there is more immune suppression.
In our study, we detected a marginal association be-
tween BV and HPV 58, a HPV 16- related types, which
is line with a study that detected a significant association
between BV and HPV16-related types [23]. The fact that
we only found a marginal significance is likely to be due
to the sample size.
In our study a HPV 18 prevalence of 17.6 was observed,
of which 54 had CIN 1 and 46 % had CIN2+. Our high
HPV 18 prevalence was significantly higher than the
10.6 % observed by de Vuyst et al. in Kenya. Women with
CD4 < 200 cells/μl appeared to have 20 % higher odds of
being infected with HPV 18, although these associations
were not statistically significant, (OR = 1.2; 95 % CI: 0.3–
4.1). However, a South African study suggested that the
prevalence of HPV 18 is inversely correlated with the level
of immunosuppression, (10.6 %) in women with CIN 2/3
and 5 % with women with normal cytology [26].
Table 4 Age-adjusted association between specific pHR/HR HPV
genotypes and CD4 count < 200 μl and CD4 count ≥350 cells/μl
(upper part); sex -adjusted associations between the three most
prevalent pHR and HR HPV genotypes and age OR from logistic
regression
HPV genotype Odds ratio 95 % CI P value*
CD4 count < 200 cells/μl
HPV 16 0.7 0.2–1.9 0.4
HPV 18 1.3 0.4–4.6 0.7
HPV 31 1.1 0.3–4.4 0.9
HPV 33 3.3 0.9–11.9 0.07
HPV 35 2.4 0.7–8.3 0.2
HPV 45 3.3 0.3–39.4 0.4
HPV 51 1.5 0.4–5.6 0.6
HPV 52 2.5 0.8 8.1 0.1
HPV 53 4.4 1.4–13.6 0.01
HPV 56 0.6 0.2–2.2 0.4
HPV 58 2.6 0.7–8.7 0.1
HPV 66 3.1 0.8–11.9 0.1
HPV 68 0.6 0.06–6.2 0.7
Multiple HPV co-infection 3.7 1.2–12.1 0.03
CD4 count ≥350 cells/μl
HPV 16 2.9 1.0–8.3 0.05
HPV 18 0.4 0.08–1.9 0.2
HPV 53 0.6 0.2–2.1 0.4
Multiple HPV co-infection 0.7 0.3–2.0 0.5
Age≥ 30 adjusted for sexual partners
HPV 16 1.1 0.3–4.1 0.8
HPV 18 2.3 0.5–11.5 0.3
HPV 53 0.9 0.2–3.2 0.8
Multiple pHR/HR HPV infections 2.4 0.7–8.9 0.2
*p-value from Wald test
Table 5 Crude association between specific HR HPV genotypes
and Bacterial vaginosis
HR HPV ORa 95 % CI P value*
Multiple pHR/HR HPV genotypes 1.0 0.4–2.8 0.9
HPV 16 0.5 0.2–1.4 0.2
HPV 18 1.0 0.3–3.3 1
HPV 52 0.6 0.2–2.0 0.4
HPV 53 0.9 0.3–2.8 0.9
HPV 58 4.1 0.8–20.0 0.07
aOR from Logistic regression
*P-value from Wald Test
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A high prevalence of HPV53 had also been observed
in other studies from Kenya. A study in HIV positive
women (median CD4 count 281/μl) from Nairobi found
high numbers of HPV53 in normal smears, whilst rare
in HIV negative women [35]. In a Nairobi cohort with a
median CD4 count of 538 cells/μl, HPV53 was among
the most common HPV type (28.5 %) [36].
Although, intuitively, it would seem reasonable that all
HPV genotypes should increase in frequency in HIV
positive individuals, strong statistically significant associa-
tions were only detected between CD4 count <200 cells/μl
and HPV53, the second most prevalent potentially onco-
genic HPV genotype in our study (aOR = 4.4; p = 0.01;
95 % CI: 1.4–13.6) and the prevalence of multiple infec-
tion. Cervical HPV infection with multiple genotypes in
HIV infected women has already been reported in re-
gional studies [37–40].
Whilst younger age has been linked with higher preva-
lence of HR-HPV genotypes in HIV-negative women [41],
we did not observe any statistically significant association
between multiple HR HPV genotypes and age, in agree-
ment with Luchters et al. [42]. One plausible explanation
given was that the absence of age effects among HIV-
infected women may have been due to a decreased ability
to clear HPV infection, reactivation of HPV or re-infection
with HPV types [12] previously cleared, all of which likely
occur more commonly in HIV-infected women.
Estimates in BV range from 20 % to 50 % in African
populations [43, 44]. A recent longitudinal study con-
ducted in Kenya, Rwanda and South-Africa in HIV-
negative women [45] reported a prevalence of 38 % [45].
The higher prevalence of BV (62 %) found in our study
can be attributed to higher risk that women with BV face
of contracting both HIV and HPV. In our study we found
that 10.7 % of women with BV harboured other STIs.
Inflammation related to BV is of concern because BV
prevalence is very high in this population. On bivariate
analysis, the association between BV and cervicitis failed
to reach significance, but this may reflect insufficient
power due to the number of BV-affected patients enrolled.
Limitations and strengths of the study
A major strength of our study is that our analysis is
limited to histological, considered to be the gold stand-
ard instead of cytological endpoints. However, the total
sample size was rather limited, which may have occulted
some plausible association of risk factors which may be
evident with a larger sample size; for this reason, adjust-
ment for various factors was limited. In addition, another
limitation relates to the cross-sectional design, where the
simultaneous data collection of BV and acquisition of HIV
infection, as well as all other variables, the temporal criter-
ion of causality is not fulfilled, thereby reversal causality
cannot be excluded. These limitations may result in a sub-
optimal internal validity of our study.
Our results can be generalized to other women receiv-
ing HIV care management. Our lack of association found
between age and the most common HPV genotypes and
multiple HPV genotypes do not appear to support the
recommendation for a screen and treat protocol for
women starting from thirty years of age. Also, a CD4
based triage may not be effective as HR HPV genotypes
are seen at different levels of immunosuppression, at
both CD4 < 200 cells/μl and CD4 count ≥350 cells/μl.
The new WHO 2014 HPV screen and treat recom-
mendation comes with close timing with the WHO 2013
recommendation to initiate HAART when asymptomatic
at CD4 count ≥350 cells/μl, which may offer opportunities
to prevent HPV 53 and multiple HPV infections, thereby
potential cervical dysplasia although it may not prevent
HPV 16 and HPV 18. However, given the limitation of this
study, including small sample size and its cross-sectional
design, a prospective cohort or RCT with a larger size is
warranted to elucidate potential relevance to plan screen-
ing according to the level of immunosuppression.
Biologic susceptibility to HPV acquisition and immune
competence for clearance of an HPV infection could be
affected by BV underscores the importance of prevention
and successful treatment of BV. In light of this finding,
the new WHO guideline to rescreen within ten years may
be more effective if it is implemented in conjunction with
a BV screening programme. Given the high prevalence of
cervicitis in this population and its potential public health
impact, it is important that BV clinical management be-
comes a major component for HIV-HPV management.
To this effect, more health care personnel, including front
line personnel, including nurses who make up the major-
ity of the work force in sub Saharan Africa should be
trained in microscope, Nugent score or Amsel reading of
BV in HIV positive women. Furthermore, symptomatic
management algorithm be established for cervicitis in this
study population and its aetiology elucidated.
Effective treatment of cervicitis resulting in significant
decreases in shedding of HIV-1 virus and infected cells
in cervical secretions depends on the aetiology of BV
and other pathogens involved implicated in cervicitis. In
this study, cervicitis was common and predominantly
non-gonococcal, although it is not possible to say that it
was non-chlamydial in etiology as CT was not diagnosed
and was found predominantly in women with BV.
Although high prevalence cervicitis has been reported
in Africa, local epidemiological data regarding the preva-
lence, etiologies, and risk factors for cervicitis in HIV-
HPV co-infected women in Kenya is lacking for guiding
syndromic management of cervicitis in this group. The
high prevalence in this study group may also affect sexual
health at a population level as inflammation in the genital
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tract results in shedding of HIV in HIV-positive women
may increase HIV to the general population. A recent meta
analysis including HIV viral load observations in blood
plasma, showed the average effect of a STI co-infection on
HIV viral load in individuals on HAART was unlikely to
decrease the effectiveness of treatment as prevention,
although there is evidence of HIV compartmentalization in
some treated patients where viral loads as measured in
genital secretions are congruent with a non-negligible
risk of transmission despite very low blood plasma viral
loads [46–48].
Our marginal association between HPV 16 genetically
related HPV 58 as well as the high prevalence of BV in
HIV-HPV co-infected women along with a high prevalence
of STIs underscores the need to elucidate its synergistic ef-
fects in increasing risk of HIV and HPV acquisition. Finally,
the high level of co-infection with STIs underscores the
value of screening for the simultaneous presence of differ-
ent genital infections in HPV positive patients. This study
also evidenced the lack of protective precautions against
STIs, notwithstanding the lack of effectiveness of condoms
reported in reducing HPV transmission [49, 50].
Conclusions
Epidemiological considerations will be needed to deter-
mine the best screening approach for different geograph-
ical settings within Kenya. A screening interval for HPV
16, HPV 53, and HPV 18, the most prevalent HPV geno-
types observed, triaged by age may not be optimal in this
study population of HIV- infected women as these geno-
types are often found in presence of other pHR/HR geno-
types. The concomitant WHO recommendation to initiate
HAART when asymptomatic at CD4 count ≥350 cells/μl,
instead of at CD4 count ≥200 cells/μl, may offer women
the possibility to ensure continuous cervical screening
during regular follow up, thereby preventing HPV 16 and
HPV 18 induced cervical dysplasia.
Given the high prevalence of HPV 53 in a HIV infected
population with abnormal cytology, its cervical carcinoma
genesis potential as a stand alone genotype and as well as its
synergism with multiple infections should be investigated.
The new WHO guideline to rescreen within ten years
may be more effective if it is interspersed with BV man-
agement. Given the high prevalence of cervicitis in this
population and its potential public health impact, it is
important that bacterial ecology monitoring becomes an
integral component of HIV-HPV management. To this
effect, there is a need for training of health care personnel
in validated point of care diagnostics for diagnosing BV in
HIV infected women. In addition, it is pivotal that the
aetiology of cervicitis be elucidated within this study
population and a symptomatic management algorithm for
cervicitis be established.
Furthermore, the association between BV and HPV 16
and its related genotypes must be further explored. A
high BV prevalence, together with high concomitant STIs
detected in our study underscores the need that the pos-
sible synergistic effects of co-infections be elucidated for
public health interest. In addition, both high concomitant
STIs prevalence and very irregular use of condoms make
the case for strengthening STD counseling within HIV
care.
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